Navigation Links
Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
Date:8/1/2012

ROCHESTER, Minn.-- Researchers at Mayo Clinic have completed the world's first genome-wide sequencing analysis of peripheral T-cell lymphomas, unlocking the genetic secrets of this poorly understood and highly aggressive cancer of the immune system.

Andrew Feldman, M.D., a Mayo Clinic pathologist and Damon Runyon Clinical Investigator, and a team of researchers affiliated with Mayo's Center for Individualized Medicine and Mayo Clinic Cancer Center, found 13 genomic abnormalities that were seen in multiple peripheral T-cell lymphomas. Of particular interest, five of these abnormalities relate to production and behavior of the p53 protein -- often called the "guardian of the genome" because of the central role it plays in regulating cell life cycles and, therefore, suppressing cancers.

The study, entitled "Genome-wide Analysis Reveals Recurrent Structural Abnormalities of TP63 and other p53-related Genes in Peripheral T-cell Lymphomas," is scheduled for early release in the online edition of the journal Blood at 9 a.m. on Wednesday, Aug. 1, 2012.

"Every time I diagnose a peripheral T-cell lymphoma, I know that two out of three patients will succumb to that lymphoma," says Dr. Feldman. "That's a very unsatisfying feeling, and I hope that our research can help change those statistics."

Peripheral T-cell lymphomas account for about 12 percent of non-Hodgkin's lymphomas and carry remarkably high mortality rates. Fewer than 35 percent of patients live five years beyond diagnosis.

New diagnostic biomarkers (chemical or genetic clues in the body's system) and treatments aimed at specific subgroups of peripheral T-cell lymphomas could lead to improved outcomes, says Dr. Feldman. Developing these, however, has been a challenge for several reasons. Lymphomas that look remarkably similar under a microscope may differ substantially in their overall prognoses and responses to treatment. Additionally, scientists and doctors have a relatively poor understanding of how peripheral T-cell lymphomas develop and proliferate.

"The most common type of T-cell lymphoma is called 'not otherwise specified.' It's basically a wastebasket diagnosis because we don't understand enough about the specific genetic abnormalities to be able to pinpoint subtypes of T-cell lymphomas that might trigger different treatments by the treating oncologist," says Dr. Feldman.

Dr. Feldman's study will be used to improve diagnostic tests and develop targeted treatments for peripheral T-cell lymphoma.

Among the key findings in the genomic abnormalities of peripheral T-cell lymphoma are:

  • Thirteen recurrent chromosomal rearrangements
  • Five of the 13 rearrangements involve p53-related genes, important for tumor-suppressor function
  • Novel rearrangements involving the TP53 homologue and TP63, which were associated with shortened survival times
  • Four interchromosomal abnormalities, including the previously known ALK and DUSP22-IRF4 translocations

  • '/>"/>

    Contact: Sam Smith
    newsbureau@mayo.edu
    507-284-5005
    Mayo Clinic
    Source:Eurekalert

    Related medicine news :

    1. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
    2. First targeted nanomedicine to enter human clinical studies
    3. Clinical insight improves treatment with new lung cancer drug
    4. Clinical news alert from the American Academy of Orthopaedic Surgeons
    5. Mayo Clinic launches whole genome breast cancer study
    6. Mayo Clinic offers newly approved treatment for acid reflux disease
    7. NYU Langone experts present research, clinical advances at neurosurgeons meeting
    8. Mayo Clinic breast cancer study finds new type of mutation
    9. Kroenke honored for outstanding contributions in clinical research training
    10. Awards celebrate clinical research that can improve health and alleviate suffering
    11. Association for Psychological Science, SAGE launch Clinical Psychological Science
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging Society ... Imaging.” The focus of ADDMI-IG will be geared towards how using molecular imaging ... Through ADDMI-IG WMIS will provide a platform for productive discussions about the implementation ...
    (Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... ... Cross Benefit Clearinghouse supporting the real time adjudication of medical service claims by ... providers using their current medical claims management software. The TransactRx Cross Benefit Clearinghouse ...
    (Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... For more than fifty years, we've suffered ... we changed our diets to conform to the latest nutritional advice – advice that was ... the NIH, more than 2 in 3 American adults are considered to be overweight and ...
    (Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is about ... and other plant-based foods, will introduce the first consumer product (a new breakfast cereal) ... Organic Products. , The transitional designation means the cereal was made using at least ...
    (Date:5/24/2016)... ... May 24, 2016 , ... According to an ... group of people randomly assigned to reduce the amount of calories they consumed by ... drop in body weight enjoyed better sleep, improved quality of life, and enhanced sexual ...
    Breaking Medicine News(10 mins):
    (Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
    (Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
    (Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
    Breaking Medicine Technology: